Clinical trials for Cystic fibrosis

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

ACT With CF Self-Help Toolkit

Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at Home

Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

Exercises' Effect on Muscle Strength, Aerobic Capacity and Respiratory Functions in Cystic Fibrosis

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

Understanding Inflammation, InFection and Interventions in Severe Exacerbations of Cystic Fibrosis

Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

Physical Impairments in Children With Cystic Fibrosis

Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring

The School-Age Children With Cystic Fibrosis and Their Parents on Health Literacy

Ensuring Access to Optimal Therapy in CF: The ENACT Study

TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

Assessing Tenapanor as a Treatment of CF-related Constipation.

A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis

Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.

Clean Air for Rare MUcociliary Clearance dIsorders

Oral Health Status of Cystic Fibrosis Patients. An Online Survey in Collaboration With the Vaincre la Mucoviscidose Patient Association.

Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

Evaluation of New Device for Beta-adrenergic Sweat Test in the Context of Stratification of Patient With Cystic Fibrosis

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

GERD in Children With Cystic Fibrosis

Hypertonic Saline in NCFB

Epididymis Protein 4 and Pulmonary Function With Quality Improvement Protocol Among Cystic Fibrosis Patients

e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population

A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

Bionic Pancreas in CFRD

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fibrosis

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)

Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis

Circadian Rhythm Disorders in Children With Cystic Fibrosis Under CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Modulators

YOGA-CF (Yoga Outcomes Get Assessed in Cystic Fibrosis)

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

CFTR Modulators in Pregnancy and Postpartum

Exercise in People With Cystic Fibrosis on CFTR Modulator Therapy

MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Regional Monitoring of CF Lung Disease

Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

Lung Transplant READY CF 2: A Multi-site RCT

CF Organization of Care in the Era of Highly Effective Modulator.

The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

FEED-Cystic Fibrosis (FEED-CF)

Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy

Closed-loop for People Living With Cystic Fibrosis Related Diabetes

Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis

Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Cardiac Structure and Function in Patients with Cystic Fibrosis

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Determinants of Daily Physical Activity Level in Patients With Cystic Fibrosis - Pilot Study Protocol

Colorectal Cancer Screening in Cystic Fibrosis

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

BEGIN Novel ImagiNG Biomarkers

4D-710 in Adult Patients With Cystic Fibrosis

Patienthèque of Finisterian (South of Brittany) Children With Cystic Fibrosis in the Time of Precision Medicine

Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

COVID-19 Antibody Responses In Cystic Fibrosis

PEP and O-PEP Device for Nebulization in Cystic Fibrosis

Airway Microbiome of Cystic Fibrosis Patients

Identification of Dysglycemia With Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis

Trikafta Exercise Study in Cystic Fibrosis

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF

COVID-19 Antibody Responses in Cystic Fibrosis

Markers of Osteoporosis in Cystic Fibrosis

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis

Regional Phenotyping of CF and Non-CF Bronchiectasis

Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis

Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening

NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria